A Phase I Clinical Trial of mTOR Inhibition with Sirolimus for Enhancing ALVAC(2)-NY-ESO-1(M)/TRICOM Vaccine Induced Anti-Tumor Immunity in Ovarian, Fallopian Tube and Primary Peritoneal Cancer

The purpose of this research is to study a vaccine treatment called recombinant canarypox-NY-ESO-1/TRICOM [also called ALVAC(2)-NY-ESO(M)/TRICOM]. The study is limited to patients with epithelial ovarian, fallopian tube or primary peritoneal carcinoma whose tumors express certain proteins (antigens) called NY-ESO-1 or LAGE-1. A vaccine is a medicine that teaches the immune system in the body to destroy harmful infections or cancer cells that do not belong in the normal tissues.

Study Number: 

I 199911

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.